Loading...

Intellectia LogoIntellectia
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
  1. Home
  2. Stock
  3. TACT
TACT logo

TACT Should I Buy

-
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
$
0.000
0.000(0.000%)
At close
0.000(0.000%)Aft-market
ET
OverviewStock Price PredictionTechnicalValuationFinancialsEarningsShould I BuyNews & Events
an image of Intellectia Logoan image of Intellectia

Most Trusted AI Platform for Winning Trades

TwitterYoutubeQuoraDiscordLinkedinTelegram

Copyright © 2026 Intellectia.AI. All Rights Reserved.

Company

  • Home
  • Contact
  • About Us
  • Press
  • Privacy
  • Terms of Service
  • Service Terms of Use

Resources

  • Blog
  • Tutorial
  • Help Center
  • Affiliate Program

Markets

  • Market Analysis
  • Crypto
  • Featured Screeners
  • AI Earnings Calendar
  • Market Movers
  • Stock Monitor
  • Economic Calendar
  • All US Stocks
  • All Cryptos

Tools

  • Dividend Calculator
  • Dividend Yield Calculator
  • Options Profit Calculator

Features

  • QuantAI Alpha Pick
  • SwingMax Portfolio
  • Swing Trading
  • AI Stock Picker
  • Whales Auto Tracker
  • Daytrading Center
  • Patterns Detection
  • AI Screener
  • Financial AI Agent
  • Backtesting Playground
  • AI Earnings Prediction
  • Stock Monitor
  • Technical Analysis

News

  • Overview
  • Top News
  • Daily Market Brief
  • Earnings Analysis
  • Newswire
  • Stock News
  • Crypto News
  • Institution News
  • Congress News
  • Monitor News

Compare

  • TradingView
  • SeekingAlpha
Intellectia

Should You Buy TransAct Technologies Inc (TACT) Today? Analysis, Price Targets, and 2026 Outlook.

Conclusion
Hold
Latest Price
3.470
1 Day change
52 Week Range
5.700
Analysis Updated At
2026/04/24
Should I buy Analysis is updated weekly. For real time "Should I Buy" analysis, please sign up to get free answers.
Sign Up

TransAct Technologies Inc (TACT) is not a strong buy at the moment for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's financial performance shows declining net income and EPS, and there are no significant positive catalysts or trading signals to support an immediate buy decision. Holding off on this stock until further positive developments is recommended.

Technical Analysis

The MACD histogram is positive and expanding, indicating a potential bullish trend. RSI is neutral at 58.841, and moving averages are converging, suggesting no clear trend. Key support and resistance levels are close to the current price, with the pivot at 3.337 and pre-market price at 3.29, slightly below support level S1 (3.249).

Options Data

Bullish
Open Interest Put-Call Ratio
Bullish
Option Volume Put-Call Ratio

Technical Summary

StrongSellSellNeutralBuyStrongBuydotted line Image
Sell
11
Buy
3

Positive Catalysts

  • Gross margin increased by 7.65% YoY in Q4 2025, indicating improved operational efficiency.

Neutral/Negative Catalysts

  • Pre-market price is down by 3.24%, and there are no significant trading trends or news to drive positive sentiment.

Financial Performance

In Q4 2025, revenue increased by 11.94% YoY to $11,453,000. However, net income dropped to -$1,131,000, down 85.79% YoY, and EPS fell to -0.11, down 86.08% YoY. Gross margin improved to 47.57%, up 7.65% YoY.

Growth

Profitability

Efficiency

Analyst Ratings and Price Target Trends

No recent analyst ratings or price target updates are available for TACT.

Wall Street analysts forecast TACT stock price to rise
1 Analyst Rating
Wall Street analysts forecast TACT stock price to rise
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 3.470
sliders
Low
5
Averages
5
High
5
Current: 3.470
sliders
Low
5
Averages
5
High
5
Roth Capital
Jeff Martin
Buy
downgrade
$6 -> $5
AI Analysis
2025-05-14
Reason
Roth Capital
Jeff Martin
Price Target
$6 -> $5
AI Analysis
2025-05-14
downgrade
Buy
Reason
Roth Capital analyst Jeff Martin lowered the firm's price target on TransAct Technologies to $5 from $6 and keeps a Buy rating on the shares. The firm notes that its prior thesis was based, in part, on a positive outcome from the strategic business review, which has now been suspended. FST and Casino & Gaming segments are performing well while the outlook for TransAct in 2025 remains breakeven to modestly negative on an adjusted EBITDA basis, the analyst tells investors in a research note.

People Also Watch